CymaBay Therapeutics Debt 2024

CymaBay Therapeutics Aktienanalyse

What does CymaBay Therapeutics do?

Cymabay Therapeutics Inc. is a biopharmaceutical company based in Newark, California. It was founded in 1988 by eight American scientists with a common goal of discovering and developing novel therapies for the treatment of serious diseases such as metabolic disorders, autoimmune diseases, and cancer. The company focuses on the regulation of bile acids and has specialized in three main areas: metabolic disorders, autoimmune diseases, and oncology. In the field of metabolic disorders, Cymabay Therapeutics has developed two important products: Arhalofenate and Seladelpar. Arhalofenate blocks the activation of the PPARy receptor, reducing insulin resistance, while Seladelpar activates the PPARd receptor, leading to increased fat burning and improved metabolism. In the field of autoimmune diseases, the company has developed a promising drug called MBX-2982, which targets the GPR119 receptor involved in insulin and glucose regulation. In oncology, Cymabay Therapeutics has developed a SIK2 inhibitor, which inhibits an enzyme necessary for tumor cell growth. The company collaborates with industry partners and public research institutions, holds over 200 patents, and aims to expand its potential. It conducts clinical trials and works with universities and public institutions to exchange technologies and knowledge. Cymabay Therapeutics strives to market its drugs globally and has established strategic partnerships in Europe and Asia. Overall, the company is a leader in discovering and developing novel drugs based on bile acids, with a diverse portfolio aimed at treating rare and serious diseases. CymaBay Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding CymaBay Therapeutics's Debt Structure

CymaBay Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing CymaBay Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to CymaBay Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in CymaBay Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about CymaBay Therapeutics stock

What is the debt of CymaBay Therapeutics this year?

CymaBay Therapeutics has a debt level of -96.9 USD this year.

What was the debt of CymaBay Therapeutics compared to the previous year?

The debt of CymaBay Therapeutics has increased by -238.62% compared to the previous year dropped.

What are the consequences of high debt for investors in CymaBay Therapeutics?

High debt can pose a risk for investors of CymaBay Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of CymaBay Therapeutics?

Low debt means that CymaBay Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from CymaBay Therapeutics affect the company?

An increase in debt of CymaBay Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of CymaBay Therapeutics affect the company?

A reduction in debt of CymaBay Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of CymaBay Therapeutics?

Some factors that can influence the debt of CymaBay Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of CymaBay Therapeutics so important for investors?

The debts of CymaBay Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can CymaBay Therapeutics take to change the debt?

To change the debt, CymaBay Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does CymaBay Therapeutics pay?

Over the past 12 months, CymaBay Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CymaBay Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of CymaBay Therapeutics?

The current dividend yield of CymaBay Therapeutics is .

When does CymaBay Therapeutics pay dividends?

CymaBay Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CymaBay Therapeutics?

CymaBay Therapeutics paid dividends every year for the past 0 years.

What is the dividend of CymaBay Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CymaBay Therapeutics located?

CymaBay Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von CymaBay Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CymaBay Therapeutics from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.

When did CymaBay Therapeutics pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of CymaBay Therapeutics in the year 2023?

In the year 2023, CymaBay Therapeutics distributed 0 USD as dividends.

In which currency does CymaBay Therapeutics pay out the dividend?

The dividends of CymaBay Therapeutics are distributed in USD.